Ricardo Parrondo

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Surbhi Sidana, Krina K. Patel, Lauren C. Peres et al. · Blood · 2024 · 124 citations · Full text

Medicine, Hematology, Oncology +14

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

Roque Díaz, Paul Nguewa, Ricardo Parrondo et al. · BMC Cancer · 2010 · 86 citations · Full text

Medicine, Oncology, Pharmacology +17

Betulinic Acid Selectively Increases Protein Degradation and Enhances Prostate Cancer-Specific Apoptosis: Possible Role for Inhibition of Deubiquitinase Activity

Teresita Reiner, Ricardo Parrondo, Alicia de las Pozas et al. · PLoS ONE · 2013 · 76 citations · Full text

Medicine, Oncology, Pharmacology +17

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

John F. Seymour, Chan Y. Cheah, Ricardo Parrondo et al. · Blood · 2023 · 66 citations

Medicine, Hematology, Oncology +14

NF-κB activation enhances cell death by antimitotic drugs in human prostate cancer cells

Ricardo Parrondo, Alicia de las Pozas, Teresita Reiner et al. · Molecular Cancer · 2010 · 62 citations · Full text

Life Sciences, Oncology, Pharmacology +17